Citi Cuts Pfizer To Sell On Oncology Drug, M&A Risks
May 16, 2017 at 13:40 PM EDT
Shares of Pfizer are falling after Citi analyst Andrew Baum downgraded the stock to Sell from Neutral and lowered his target price to $31 from $38.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.